ORIC Oric Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ORIC

Price (delayed)

$7.67

Market cap

$418.41M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.99

Enterprise value

$392.17M

ORIC Pharmaceuticalsis a clinical stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. ORIC's lead product candidate, ORIC-101, is a potent and selective small molecule antagonist ...

Highlights
The EPS has increased by 14% year-on-year and by 9% since the previous quarter
Oric Pharmaceuticals's equity has increased by 15% YoY but it has decreased by 8% QoQ
The quick ratio has declined by 34% since the previous quarter and by 18% year-on-year
ORIC's net income is down by 2.4% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://oricpharma.com
Peers: OMGA

Key stats

What are the main financial stats of ORIC
Market
Shares outstanding
54.55M
Market cap
$418.41M
Enterprise value
$392.17M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.69
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$93.21M
EBITDA
-$92.2M
Free cash flow
-$77.83M
Per share
EPS
-$1.99
Free cash flow per share
-$1.36
Book value per share
$4.54
Revenue per share
$0
TBVPS
$4.78
Balance sheet
Total assets
$274.34M
Total liabilities
$26.92M
Debt
$0
Equity
$247.41M
Working capital
$213.29M
Liquidity
Debt to equity
0
Current ratio
12.26
Quick ratio
12
Net debt/EBITDA
0.28
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-35.9%
Return on equity
-39.6%
Return on invested capital
-51.8%
Return on capital employed
-36.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ORIC stock price

How has the Oric Pharmaceuticals stock price performed over time
Intraday
4.78%
1 week
5.07%
1 month
22.13%
1 year
104.53%
YTD
30.22%
QTD
26.78%

Financial performance

How have Oric Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$101.47M
Net income
-$93.21M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 10% year-on-year and by 3% since the previous quarter
ORIC's net income is down by 2.4% year-on-year

Growth

What is Oric Pharmaceuticals's growth rate over time

Valuation

What is Oric Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.69
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 14% year-on-year and by 9% since the previous quarter
The stock's P/B is 34% more than its last 4 quarters average of 1.2
Oric Pharmaceuticals's equity has increased by 15% YoY but it has decreased by 8% QoQ

Efficiency

How efficient is Oric Pharmaceuticals business performance
Oric Pharmaceuticals's return on invested capital has increased by 14% YoY and by 3.9% QoQ
The ROA has declined by 6% year-on-year but it is up by 2.7% since the previous quarter
The return on equity has declined by 6% year-on-year but it is up by 2.7% since the previous quarter

Dividends

What is ORIC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ORIC.

Financial health

How did Oric Pharmaceuticals financials performed over time
The quick ratio has declined by 34% since the previous quarter and by 18% year-on-year
The company's current ratio fell by 34% QoQ and by 18% YoY
ORIC's debt is 100% smaller than its equity
Oric Pharmaceuticals's equity has increased by 15% YoY but it has decreased by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.